Switching off a single enzyme in immune cells protected mice from obesity, type 2 diabetes, and fatty liver disease in a new study, offering a potential new treatment target for metabolic disorders.

The prevalence of type 2 diabetes and obesity worldwide is increasing, and these two conditions have a bidirectional and linear relationship. Obesity worsens the development of type 2 diabetes by ...

A deep dive into the scientific shift toward multi-target obesity therapeutics and its implications for metabolic health and ...

Over 27 percent of adults worldwide with obesity qualify for GLP-1 weight loss medicines but access remains unequal.

Obesity is one of the most common health issues in the world, which also triggers other diseases.Prolonged obesity can ...

The intricate relationship between diet, metabolic disorders, and cancer progression has garnered significant attention in ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Adolescents with overweight or impaired glucose ...

Youth with obesity but without type 2 diabetes were 31% less likely to develop type 2 diabetes if they were prescribed a glucagon-like peptide 1 (GLP-1) receptor agonist medication instead of an older ...

Sarcopenic obesity is a condition that occurs when you have both obesity (excess body weight) and sarcopenia (low muscle mass). Up to 23% of people may have sarcopenic obesity. Sarcopenic obesity has ...